

Code	Name	Partner	Disease domain	Mode of action	Current phase	Remarks	Questions
GLPG0187			Bonecancer	Integrin receptor antagonist	Stopped after Phase 1		
GLPG0259		Janssen	RA (Rheumatoid Arthritis)	MAPKAPK5 inhibitor	Stopped after Phase 2		
GLPG03xx			Undisclosed indication	Undisclosed indication	Stopped Preclinical		Number?
GLPG0492			MD (Muscular Dystrophy)	Androgen receptor modulator	Stopped after Phase 1		
GLPG0555		Before Glaxo SmithKline	Lupus, Psoriasis, UC	JAK1 inhibitor	Phase 1, possibly active again in 2020	Backup of GLPG0778	JAK1 or other MoA?
GLPG0634		Rigobio	RA (Rheumatoid Arthritis)	JAK1 inhibitor	Phase 3 (FINCH 1,2,3), completed, (FINCH 4) May '20 com	Approved in Europe, Japan	
		Gilead (Before AbbVie)	UC (Ulcerative Colitis)	JAK1 inhibitor	Phase 3 (SELECTION 1), May '20 completed		
		Gilead (Before AbbVie)	CD (Crohn's Disease)	JAK1 inhibitor	Phase 3 (DIVERGITY 1), Nov '21 completed		
		Gilead (Before AbbVie)	Small bowel CD (Crohn's Disease)	JAK1 inhibitor	Phase 2, July '20 completed		
		Gilead (Before AbbVie)	Perianal Fistulizing CD (Crohn's Disease)	JAK1 inhibitor	Phase 2 (DIVERGENT 2), Jan '21 completed		
		Gilead (Before AbbVie)	SS (Sjögren Syndrome)	JAK1 inhibitor	Phase 2, Completed		
		Gilead (Before AbbVie)	AS (Ankylosing Spondylitis) (Bechterew)	JAK1 inhibitor	Phase 3 (SEALION 1, 2), Jul '24 completed		
		Gilead (Before AbbVie)	PsA (Psoriatic Arthritis)	JAK1 inhibitor	Phase 3 (PENGUIN 1,2), Oct '21 completed and May '22 completed		
		Gilead (Before AbbVie)	CLE (Cutaneous Lupus Erythematosus)	JAK1 inhibitor	Phase 2, Dec '19 completed		
		Gilead (Before AbbVie)	LMN (Lupus Membranous Nephropathy)	JAK1 inhibitor	Phase 2, Feb '20 completed		
		Gilead (Before AbbVie)	Uveitis	JAK1 inhibitor	Phase 2 (HUMBOLDT), July '22 completed		
GLPG0778		Glaxo SmithKline	Lupus, Psoriasis, UC	JAK1 inhibitor	Stopped after Phase 2a		
GLPG08xx			Undisclosed indication	Undisclosed indication	Stopped Preclinical		Number?
GLPG0974		Before Glaxo SmithKline	IBD (Inflammatory Bowel Disease)	SPR3 inhibitor / FFAR2	Stopped after Phase 2		
GLPG10xx			Undisclosed indication	Undisclosed indication	Stopped Preclinical		Number?
GLPG1175		Before Glaxo SmithKline	Undisclosed indication	Undisclosed indication	Stopped Preclinical		
GLPG1205		Before Janssen	IPF (Idiopathic Pulmonary Fibrosis)	SPR3 inhibitor / FFAR2	Phase 2 (PHTA), Aug '20 completed		
GLPG1332		Before Servier	OA (Osteoarthritis)	Undisclosed indication	Stopped Preclinical		
GLPG1492			MSA	Antibiotic	Stopped Preclinical		
GLPG1577		Before Glaxo SmithKline	Undisclosed indication	Undisclosed indication	Stopped Preclinical		
GLPG1690		Zincvax	IPF (Idiopathic Pulmonary Fibrosis)	Juvsaven inhibitor	Phase 2 (PHTA), Dec '21 completed	Orphan drug	
GLPG1790		Before Janssen	RA (Rheumatoid Arthritis), SLE (Systemic Lupus Erythematosus), Scleroderma	Juvsaven inhibitor	Phase 2 (INDIGEN), Sept '22 completed	Orphan drug	
GLPG1837		AbbVie	CF (Cystic Fibrosis)	Gabrin Receptor tyrosine kinase inhibitor	Stopped after Phase 2 (SAPHIRA)	Continue with GLPG1401	
GLPG1972		Servier	OA (Osteoarthritis)	16 potentiator	Stopped after Phase 2 (ROCCELLA)	Seriously continued in other disease	
GLPG20xx			Undisclosed indication	Undisclosed indication	Stopped Preclinical		Number?
GLPG2196		Before Janssen	COPD (Chronic Obstructive Pulmonary Disease)	SPR3 antagonist/CFR Potentiator	Stopped Preclinical	Backup of GLPG1205	
GLPG2222		AbbVie	CF (Cystic Fibrosis)	16 E2 corrector	Phase 2, Combi ABBV-2222-ABBV-3067, Aug '21		
GLPG2384		Before Janssen	Undisclosed indication	SPR3 antagonist	Preclinical	Backup of GLPG1205	Still active?
GLPG2451		AbbVie	CF (Cystic Fibrosis)	26 potentiator	No study with AbbVie		Still active?
GLPG2534			AD (Atopic Dermatitis)	Preclinical			Still active?
GLPG2665		AbbVie	CF (Cystic Fibrosis)	18 E2 corrector		Continue with GLPG237	
GLPG2737		Before AbbVie	Autosomal Dominant Polycystic Kidney Disease (ADPKD)	26 E2 corrector	Phase 2 started October 2020, now '22 completed	Rights outside CF for GLPG	
GLPG2851		AbbVie	CF (Cystic Fibrosis)	26 E3 corrector	No study with AbbVie		Still active?
GLPG2938			IPF (Idiopathic Pulmonary Fibrosis)	IPF	Stopped Preclinical	Continue with GLPG1499	
GLPG3067		AbbVie	CF (Cystic Fibrosis)	36 potentiator	Phase 2, Combi ABBV-2222-ABBV-3067, Aug '21		
GLPG3121		Gilead	Inflammation	JAK1/3 inhibitor	Phase 1	Stopped after Phase 1 due to lac	
GLPG3221		AbbVie	CF (Cystic Fibrosis)	36 E2 corrector		Continue with GLPG3748	
GLPG3312		Toledo	Inflammation	SK1/2/3 inhibitor?	No longer actively developed	Gen 1, Toledo	
GLPG3499			IPF (Idiopathic Pulmonary Fibrosis)	IPF	Stopped in IPF preclinical		Still active?
GLPG3535		Calcian	Pain	Preclinical			MoA?
GLPG3667		Gilead	Inflammation	Preclinical	Phase 1, Feb '20 completed		MoA?
GLPG3748		AbbVie	CF (Cystic Fibrosis)	46 E2 corrector	No study with AbbVie		Still active?
GLPG3808			Undisclosed indication	Preclinical			Disease? MoA?
GLPG3970		Toledo	Psoriasis	SK2/3 inhibitor?	Phase 1 (CALOSOMA), Apr '21 completed	Gen 2 Toledo (More selective)	MoA?
			UC (Ulcerative Colitis)	SK2/3 inhibitor?	Phase 2 (SEA/TURTLE), Jun '21 completed	Gen 2 Toledo (More selective)	MoA?
			RA (Rheumatoid Arthritis)	SK2/3 inhibitor?	Phase 2 (LADYBUG), May '21 completed	Gen 2 Toledo (More selective)	MoA?
			SS (Sjögren Syndrome)	SK2/3 inhibitor?	Expected to start early '21	Gen 2 Toledo (More selective)	MoA?
			SLE (Systemic Lupus Erythematosus)	SK2/3 inhibitor?	Expected to start early '21	Gen 2 Toledo (More selective)	MoA?
GLPG4059			Diabetes Type 2	Novel MOA that does not hit triglyceride	Preclinical, Phase 1 expected in 2020		
GLPG4124		Gilead	Fibrosis				MoA?
GLPG4259		Gilead	Inflammation				Backup of?
GLPG4399		Toledo	Inflammation	SK3 inhibitor?	Preclinical, Phase 1 in RA start in '20	Gen 3 Toledo (More selective)	MoA?
GLPG4471		Gilead	Inflammation				Backup of?
GLPG4586			Fibrosis				Disease? MoA?
GLPG4605		Toledo	Fibrosis	SK2/3 inhibitor?			Gen 2 Toledo (More selective)
GLPG47XX							
MOR106		Morpholys and Novartis	Atopic Dermatitis	1-57C	Stopped after Phase 2 (GUANA) (GEOX)		

Legend

- xxx Stopped
- xxx Active

Disease domains

- xxx Idiopathic Pulmonary Fibrosis
- xxx Cystic Fibrosis
- xxx Inflammation
- xxx Osteoarthritis
- xxx Cancer
- xxx Other, Undisclosed or Unknown

Galápagos

Pioneering for patients

We discover We dare We care